Vascular endothelial growth factor A gene (VEGFA) polymorphisms and expression of VEGFA gene in lung cancer patients of Kashmir Valley (India)

Tumor Biology

Volumn 33, Issue 3, 2012, Pages 833-839

  Naik, Niyaz A ^a   Bhat, Imtiyaz A ^a   Afroze, Dil ^a   Rasool, Roohi ^a   Mir, Hyder ^a   Andrabi, Syed Irtiza ^a   Shah, Sonaullah ^a   Siddiqi, Mushtaq A ^a   Shah, Zafar A ^a  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Expression; Kashmir; Lung; Polymorphism; VEGFA

Indexed keywords

GENOMIC DNA; RNA; MESSENGER RNA; VASCULOTROPIN A;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDIA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR ENDOTHELIAL GROWTH FACTOR A GENE; CAUCASIAN; GENETICS; GENOTYPE; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK FACTOR;

ADULT; AGED; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; INDIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863603747     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0306-y     Document Type: Article

References (53)

1. Alon, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024-8.
2. •- untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002;51:1635-9.
3. Balasubramanian, et al. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer. 2007;121:1009-16.
4. Bell, et al. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim. 1999;35:533-42.
5. Brem, et al. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res. 1976;36:2807-12.
6. Cao, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA. 1998;95:14389-94.
7. Connolly, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84:1470-8.
8. Ferrara, Davis-Smyth. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25.
9. Folkman. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-6.
10. Fontanini, et al. Expression of vascular endothelial growth factor mRNAin non-small cell lung carcinomas. Br J Cancer. 1999;79:363-9.
11. Fontanini, et al. Vascular endothelial growth factors is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res. 1997;3:861-5.
12. Formento, et al. Influence of the VEGF-A 936C > T germinal polymorphism on tumoral VEGF expression in head and neck cancer. Pharmacogenomics. 2009;10:1277-83.
13. Gasparini, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst. 1997;89:139-47.
14. Graeven, et al. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol. 1999;125:621-9.
15. Grugel, et al. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem. 1995;270:25915-9.
16. Hanahan, Folkman. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-64.
17. Hefler, et al. Vascular endothelial growth factor polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res. 2007;13:898-901.
18. Holmgren, et al. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149-53.
19. Howell, et al. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun. 2002;3:229-32.
20. Hurwitz, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.
21. Jain, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther. 2009;8:2496-508.
22. Jin, et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res. 2005;11:3647-53.
23. Joseph, et al. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res. 1997;3:2507-11.
24. Kabbinavar, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23:3706-12.
25. Kataoka, et al. Population-based case.control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev. 2006;15:1148-52.
26. Kieser, et al. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene. 1994;9:963-9.
27. Koukourakis, et al. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 2004;46:293-8.
28. Krippl, et al. A common 936C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 2003;106:468-71.
29. Ku, et al. Vascular endothelial growth factor gene.460C/T polymorphism is a biomarker for oral cancer. Oral Oncol. 2005;41:497-502.
30. Linderholm, et al. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol. 1998;16:3121-8.
31. Liotta, et al. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 1974;34:997-1004.
32. Lu, et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res. 2005;65:5015-9.
33. Michael, et al. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 2004;46:293-8.
34. Norrby. Angiogenesis: new aspects relating to its initiation and control. APMIS. 1997;105:417-37.
35. Ohta, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res. 1996;2:1411-6.
36. Ohta, et al. Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Brit J Cancer. 1997;76:1041-5.
37. Pepper, et al. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein. 1996;49:138-62.
38. Phillips, et al. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo. 1994;8:961-5.
39. Plate, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845-8.
40. Polverini. How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases. Eur J Cancer. 1996;32A:2430-7.
41. Rebecca, et al. VEGF polymorphisms and survival in early-stage non-small cell lung cancer. J Clin Oncol. 2008;26(6):856-62.
42. Renner, et al. A common 936C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial factor plasma levels. J Vasc Res. 2000;37:443-8.
43. Schneider, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;26:4672-8.
44. Sfar, et al. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine. 2006;35:21-8.
45. Stevens, et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63:812-6.
46. Tischer, et al. The human gene for vascular endothelial growth factor. Multiple proteins forms are encoded through alternative exon splicing. J Biol Chem. 1991;266:11947-54.
47. Tolentino, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996;114:964-70.
48. Torimura, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol. 1998;29:986-91.
49. Tzanakis, et al. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol. 2006;94:624-30.
50. Vincenti, et al. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996;93:1493-5.
51. Watson, et al. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12:1232-5.
52. Yang, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-34.
53. Zhai, et al. Genotypes and haplotypes of VEGF gene are associated with higher ARDS mortality and lower VEGF plasma levels. Thorax. 2007;62:718-22.